Compare SLDB & CCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLDB | CCB |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2017 | 2018 |
| Metric | SLDB | CCB |
|---|---|---|
| Price | $8.11 | $41.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | $16.36 | ★ $126.67 |
| AVG Volume (30 Days) | ★ 1.2M | 181.9K |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.97 | N/A |
| EPS | N/A | ★ 0.78 |
| Revenue | ★ $8,094,000.00 | N/A |
| Revenue This Year | N/A | $96.61 |
| Revenue Next Year | N/A | $22.66 |
| P/E Ratio | ★ N/A | $51.40 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.79 | $36.61 |
| 52 Week High | $11.45 | $120.05 |
| Indicator | SLDB | CCB |
|---|---|---|
| Relative Strength Index (RSI) | 43.63 | 12.38 |
| Support Level | $6.25 | N/A |
| Resistance Level | $8.67 | $83.23 |
| Average True Range (ATR) | 0.45 | 4.03 |
| MACD | -0.16 | -4.11 |
| Stochastic Oscillator | 24.95 | 6.15 |
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
Coastal Financial Corp is a bank holding company. Through its subsidiaries, the company conducts its business in three reportable segments which include, Community Bank, CCBX, and Treasury and Administration. The Community Bank segment includes all community banking activities, with a primary focus on providing various banking products and services to consumers and small to medium-sized businesses. The CCBX segment provides Banking as a Service (BaaS) that allows its broker dealers and digital financial service partners to offer their customers banking services, and the Treasury and administration segment includes treasury management, overall administration, and all other aspects of the company.